Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Auckland PrEP demonstration study in high-risk gay and bisexual men
ACTRN12616001387415Phase 4Completed
- Sponsor
- Auckland District Health Board
- Start
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of emtricitabine + tenofovir disoproxil in human immunodeficiency virus infection (HIV), sponsored by Auckland District Health Board. Primary endpoints: HIV seronegativity at study end, Acceptability of HIV PrEP and 1 more. Started Feb 2017; status: completed.
02
Drugs
emtricitabine + tenofovir disoproxil
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on ACTRN12616001387415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616001387415.